This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Isis Announces Antisense Targeting Of HBV Produces Dose-Dependent Reductions In Hepatitis B Virus In An Animal Model Of HBV

CARLSBAD, Calif., March 24, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that treatment with an antisense compound targeting hepatitis B virus (HBV) produced dose-dependent reductions in all measured liver and serum viral markers of HBV infection in animal models of HBV infection.  These data will be presented at the 49 th annual meeting of the European Association for the Study of the Liver (EASL) by Dr. Gaetan Billioud, from the Scripps Research Institute in London, England.  Isis is currently evaluating antisense targeting of HBV with ISIS-HBV Rx in a Phase 1 study in healthy volunteers. 

Isis Pharmaceuticals, Inc.

"Hepatitis B virus infection is a serious health problem that can lead to significant and potentially fatal health conditions, including cirrhosis, liver failure and liver cancer. Chronic HBV infection is one of the most common persistent viral infections in the world. Currently available therapies, although effective in reducing circulating HBV in the blood, do not efficiently inhibit HBV antigen production and secretion, which are associated with poor prognosis and increased risk of liver cancer," said Dr. Stefan Wieland, assistant professor of experimental virology at The Scripps Research Institute.  "These data are encouraging as they demonstrate that antisense drugs are able to efficiently reduce HBV-associated antigens as well as circulating HBV in an animal model of disease.  As such, these results provide support for the development of ISIS-HBV Rx for the treatment of patients with chronic HBV infection."

These preclinical data, which will be presented by Dr. Gaetan Billioud from The Scripps Research Institute during a presentation on April 12 at EASL, demonstrate that antisense targeting of HBV RNA could be an effective approach to treating patients with chronic HBV infection.  In this study, an antisense compound targeting HBV produced dose-dependent reductions of HBV-associated antigens, including  HBsAg  (hepatitis B surface antigen), which is present in both acute and chronic infections and is associated with a poor prognosis in patients with chronic HBV infection.  In addition, other measures of viral infection were reduced in both the liver and serum in this mouse model of disease.   

"While chronic hepatitis B virus is currently treated with oral antiviral agents or injectable interferons, these treatments do not clear HBV and do not effectively clear HBV antigens from these patients.  As a result, patients are unable to fully control HBV infection and achieve sustained disease remission.  Many of these patients are at elevated risk for severe liver complications such as cirrhosis and primary liver cancer.  By targeting and suppressing viral mRNAs in the liver, treatment with ISIS-HBV Rx added to current therapies could result in greater viral inhibition and permit greater immune system activity against the virus," said Richard Geary, Ph.D., senior vice president, development at Isis.   "Based on all of the preclinical data, including the animal data that will be presented at EASL, we initiated a Phase 1 study of ISIS-HBV Rx late last year, which we plan to complete this year."

The Phase 1 study of ISIS-HBV Rx is a randomized, placebo-controlled, dose-escalation study in approximately 30 healthy volunteers.  This study is designed to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of ISIS-HBV Rx.  ISIS-HBV Rx, formerly referred to as ISIS-GSK3 Rx, is an investigational drug that is designed to target viral mRNA and reduce the production of viral proteins associated with HBV infection and replication.  ISIS-HBV Rx is part of Isis' alliance with GSK.  Isis will develop ISIS-HBV Rx to completion of Phase 2 proof-of-concept, after which GSK has an exclusive option to in-license and further develop and commercialize ISIS-HBV Rx. Isis has already earned $10 million in milestone payments from GSK for ISIS-HBV Rx and is eligible to earn additional pre-licensing milestone payments from GSK as ISIS-HBV Rx advances in development.  Isis is also eligible to receive double-digit royalties on sales of ISIS-HBV Rx

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 31 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO ®, in the United States and other countries for the treatment of patients with homozygous FH.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT

This press release includes forward-looking statements regarding Isis' collaboration with GSK, the discovery, development, activity, therapeutic potential and safety of ISIS-HBV Rx and the therapeutic potential of discovering a drug to treat chronic HBV infection.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2013, which is on file with the SEC. Copies of this and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,976.31 +263.65 1.49%
S&P 500 2,086.24 +25.22 1.22%
NASDAQ 4,947.4410 +56.2220 1.15%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs